Literature DB >> 6306468

HLA-D region beta-chain DNA endonuclease fragments differ between HLA-DR identical healthy and insulin-dependent diabetic individuals.

D Owerbach, A Lernmark, P Platz, L P Ryder, L Rask, P A Peterson, J Ludvigsson.   

Abstract

The human HLA-D histocompatibility region encodes class II antigens each of which consists of two polypeptide chains (alpha and beta) inserted in the plasma membrane. These molecules are implicated in the regulation of the immune response but several human diseases are also found to be associated with certain HLA-DR antigens. The occurrence of insulin-dependent (type I) diabetes (IDDM) is strongly associated with HLA-DR3 and/or 4 (ref. 5). The class II antigens, however, show a marked genetic polymorphism associated with the beta-chains which seem, from hybridization studies, to be encoded by several genes. We have therefore used the beta-chain cDNA probe, pDR-beta-1 (refs 8, 10) to test whether there are differences in hybridization pattern between DNA from healthy individuals and diabetic patients, after digestion with restriction endonucleases. Among the HLA-DR 4 and 3/4 individuals, the IDDM patients showed an increased frequency of a PstI 18 kilobase (kb) fragment. A BamHI 3.7 kb fragment, frequent among controls (30-40%), was rarely detected in the IDDM patients (0-2%). These differences may be related to susceptibility to develop the disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6306468     DOI: 10.1038/303815a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  64 in total

Review 1.  Genetic analysis of susceptibility to type 1 diabetes.

Authors:  J A Todd
Journal:  Springer Semin Immunopathol       Date:  1992

Review 2.  Genetic susceptibility in type 1 diabetes and its associated autoimmune disorders.

Authors:  Akane Ide; George S Eisenbarth
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

3.  Trans-racial studies implicate HLA-DQ as a component of genetic susceptibility to type 1 (insulin-dependent) diabetes.

Authors:  J Fletcher; C Mijovic; O Odugbesan; D Jenkins; A R Bradwell; A H Barnett
Journal:  Diabetologia       Date:  1988-12       Impact factor: 10.122

4.  Novel HLA class II-associated structural patterns in coeliac disease and type I diabetes.

Authors:  N Fernandez; G A Hitman; H Festenstein; L Garde; M Labeta; J A Walker-Smith; J A Sachs
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

5.  A systematic study of HLA class II-beta DNA restriction fragments in insulin-dependent diabetes mellitus.

Authors:  O Cohen-Haguenauer; E Robbins; C Massart; M Busson; I Deschamps; J Hors; J M Lalouel; J Dausset; D Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

6.  A 3.5 kilobase Taq I restriction fragment of genomic DNA segregates with HLA-B27.

Authors:  J A Trapani; C A Mickelson; I F McKenzie
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

Review 7.  Immunological aspects on IDDM in children.

Authors:  J Ludvigsson
Journal:  Indian J Pediatr       Date:  1989 Nov-Dec       Impact factor: 1.967

8.  Class II HLA-DC beta-chain DNA restriction fragments differentiate among HLA-DR2 individuals in insulin-dependent diabetes and multiple sclerosis.

Authors:  D Cohen; O Cohen; A Marcadet; C Massart; M Lathrop; I Deschamps; J Hors; E Schuller; J Dausset
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

9.  Six HLA-D region alpha-chain genes on human chromosome 6: polymorphisms and associations of DC alpha-related sequences with DR types.

Authors:  R S Spielman; J Lee; W F Bodmer; J G Bodmer; J Trowsdale
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

10.  Unusual clustering of diseases in a Canadian Old Colony (Chortitza) Mennonite kindred and community.

Authors:  M A Jaworski; J D Slater; A Severini; K R Hennig; G Mansour; J G Mehta; R Jeske; J Schlaut; C Y Pak; J W Yoon
Journal:  CMAJ       Date:  1988-06-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.